Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator In Vivo Tool Compound
ACS Chemical Neuroscience · 2025
DOI: 10.1021/acschemneuro.5c00032 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Kentaro Yashiro und 15 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery Chemistry, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan. Hauptthemen laut MEDLINE: Potassium Channels, Tandem Pore Domain, Analgesics, Central Nervous System. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Herein we describe our initial work on the K2P family of potassium ion channels with the chemical optimization and characterization of a novel series of TWIK-Related K+ Channel (TREK)-1/2 dual activators and TREK-2 preferring activators derived from a high-throughput screening hit. The exercise provided TREK activators with good CNS penetration and others with low CNS exposure to enable exploration of both central and peripheral TREK activation. From this, ONO-2920632 (VU6011887 = 19b) emerged as a reasonably potent (human Tl+; TREK-1 EC50 = 2.8 μM (95% Emax), TREK-2 EC50 = 0.30 μM (184% Emax)), first-generation CNS penetrant (rat Kp = 0.37) in vivo tool compound with selectivity versus the other K2P channels (>91-fold selective vs TASK1, TASK2, TASK3, TRAAK, TWIK2, and 31-fold selective vs TRESK) and no significant activity in a large ancillary pharmacology panel. ONO-2920632 (VU6011887) displayed robust, dose dependent efficacy when dosed orally in a mouse pain model (acetic acid writhing assay), where it was equipotent at 3 mg/kg to the assay standard indomethacin at 10 mg/kg. The therapeutic potential of TREK channel activation has long been hampered by a lack of selective, small molecule tools, and this work provides a variety of in vivo tool compounds for the community.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Discovery Chemistry, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.
- Research Center of Neurology, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.
- Pharmacokinetic Research, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.
- Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
- Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
- Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
ORCID-Profile: Haruto Kurata, Craig W Lindsley
Zitieren
APA
Yashiro, K., Iwaki, Y., Urata, H., Kokubo, M., Mori, T., Sekioka, Y., Isami, K., Kato, J., Wieting, J., McGowan, K. M., Bridges, T. M., Boutaud, O., Engers, D. W., Denton, J. S., Kurata, H., & Lindsley, C. W. (2025). Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator In Vivo Tool Compound. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00032
Vancouver
Yashiro K, Iwaki Y, Urata H, Kokubo M, Mori T, Sekioka Y, et al. Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator In Vivo Tool Compound. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00032
BibTeX
@article{Yashiro2025,
author = {Yashiro, Kentaro and Iwaki, Yuzo and Urata, Hirohito and Kokubo, Masaya and Mori, Takahiro and Sekioka, Yoko and Isami, Koichi and Kato, Junya and Wieting, Joshua and McGowan, Kevin M and Bridges, Thomas M and Boutaud, Olivier and Engers, Darren W and Denton, Jerod S and Kurata, Haruto and Lindsley, Craig W},
title = {Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator In Vivo Tool Compound},
journal = {ACS Chemical Neuroscience},
year = {2025},
doi = {10.1021/acschemneuro.5c00032}
}
EUVIMED